Carlos Galamba
With more than 18 years of experience in the IVD sector, including hands-on work as a scientist in transfusion medicine and infectious disease diagnostics, and regulatory review experience at BSI, one of the EU's largest Notified Bodies, Carlos Galamba brings a uniquely integrated perspective to IVD regulatory strategy. Their work spans Class C/D IVDs, companion diagnostics, NGS-based assays, and software-based IVDs, with a current advisory role to the European Commission on regulatory matters. At MDx CRO, they lead regulatory strategy for complex IVD programs across EU IVDR, FDA, and global markets.
Latest Articles
Blog & Insights
Performance studies in gene therapy trials: from assay cut-offs to clinical impact
Last Updated: 2026-05-19
Read more
Blog & Insights
Events & Conferences
MDx CRO at MPP 2025: Aligning Companion Diagnostics and Drug Development under IVDR
Last Updated: 2026-02-24
Read more
Events & Conferences
MDx CRO at ESMO 2025 (Berlin): Advancing IVDR Transitions & Combined Clinical Trials
Last Updated: 2026-02-24
Read more
Blog & Insights
TGA guidance (Oct 2025): IVD Companion Diagnostics (CDx) Requirements in Australia
Last Updated: 2026-05-19
Read more
Case studies
Events & Conferences
MDx to Present ESMO 2025 Poster on IVDR CE Marking for Large Germline NGS Panels
Last Updated: 2026-08-12
Read more
Blog & Insights